Back to top

Image: Bigstock

Top Ranked Value Stocks to Buy for April 20th

Read MoreHide Full Article

Here are four stocks with buy rank and strong value characteristics for investors to consider today, April 20th:

Regional Management Corp. (RM - Free Report) : This diversified consumer finance company has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 1.5% over the last 60 days.

Regional Management has a price-to-earnings ratio (P/E) of 3.49, compared with 5.80 for the industry. The company possesses a Value Score of A.

BGC Partners, Inc. (BGCP - Free Report) : This operates as a brokerage and financial technology company has a Zacks Rank #1, and seen the Zacks Consensus Estimate for its current year earnings rising 4.8% over the last 60 days.

BGC Partners has a price-to-earnings ratio (P/E) of 4.16, compared with 13.60 for the industry. The company possesses a Value Score of A.

Green Brick Partners, Inc. (GRBK - Free Report) : This homebuilding and land development company has a Zacks Rank #1, and seen the Zacks Consensus Estimate for its current year earnings rising 37.4% over the last 60 days.

Green Brick Partners has a price-to-earnings ratio (P/E) of 4.95, compared with 22.30 for the industry. The company possesses a Value Score of A.

PennyMac Financial Services, Inc. (PFSI - Free Report) : This company that engages in the mortgage banking and investment management activities has a Zacks Rank #1, and seen the Zacks Consensus Estimate for its current year earnings rising 42.1% over the last 60 days.

PennyMac Financial Services has a price-to-earnings ratio (P/E) of 3.52, compared with 137.20 for the industry. The company possesses a Value Score of A.

See the full list of top ranked stocks here.

Learn more about the Value score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>